Latest news with #AtopicDermatitis
Gulf Today
12-07-2025
- Health
- Gulf Today
Dermatology campaign to focus on eczema prevention
A genetically-induced skin disease, commonest in boys and women shall be the centrepiece campaign of dermatologists in the UAE and a Saudi-Arabia-headquartered pharmaceutical firm, this academic year until July 2026. The partnership between the Emirates Dermatology Society (EDS) and the Jamjoom Pharma, which has branches in Dubai and Cairo, Egypt, was formalised with the July 4 signing of the Memorandum of Understanding (MoU) in the capital, way ahead of the 'ECZPLORE' September launch. It is 'ECZPLORE' because the campaign is about eczema. EDS president Dr. Ayman Al Naeem told Gulf Today on Friday: 'Eczema has become one of the most pressing skin health issues in the UAE. It affects one in five children and often gets worse, because of the heat, the humidity and the air-conditioning; generally our climate.' Referring to the EDS data, when enquired regarding the youngest and oldest patients, the gender ratio, and the prevalence in the country's multi-racial landscape, Al Naeem said: 'The condition can appear as early as the first few weeks of life, although such an early onset is rare.' Rare too, it is, among septuagenarians and octogenarians who have been found to also be suffering from the disease, which counts 'environmental factors' namely 'allergens, climate, stress and irritants,' particularly those with 'family history and mutations in skin barrier genes like filaggrin,' a protein – a as a cause. These, as in the 'Atopic Dermatitis Insights on Global Prevalence, Health Care Implications and the Impact of COVID-19,' Kyung Hee University College of Medicine (Seoul, South Korea) medical student-researcher Jiyen Oh, noted that by 2050, global incidence would be at 148 million cases 'with minimal change in the prevalence rate.' The research was published in 'The Lancet Respiratory Medicine.' Oh studied the co-relation of eczema, otherwise known as Atopic Dermatitis, with asthma and COVID-19. Oh wrote that the skin disease shall have higher incidences in 'high-income countries likely influenced by environmental factors, urbanisation and better diagnostic capabilities.' Al Naeem pointed out that a campaign is crucial because 'beyond the skin, eczema affects how children sleep, play, learn and interact. For many families, it is a daily emotional and physical struggle.' Jamjoom Pharma-Gulf/Levant/Export Markets general manager Dr. Samer Lezzaiq said they are looking forward at partnerships with relevant authorities and educational institutions even as 'five major schools across the five largest cities in the UAE will be targeted.' 'This campaign is a national call to action designed to reach over one million individuals through digital platforms, schools and on-ground events,' Lezzaiq added, stressing that these are necessary; for, apart from the basic general knowledge, 'guidance on lifestyle modifications' are key to help patients and their households. 'Selection of the five major schools will be randomised. Primary targets are children between two and 12 years old,' said Lezzaiq. He answered in the negative when asked if secondary and tertiary educational institutions were included, as teenagers and young adults may be eczema sufferers as well: 'The age group most affected are the ages two and 12. Secondary schools, colleges, and universities fall outside of the current scope.' From Al Naeem: 'The highest prevalence is typically seen during childhood. In terms of gender distribution, it is more common in boys. This trend shifts in adulthood, with a higher prevalence observed in women.' He repeated Lezzaiq's mention of alterations in lifestyle, pointing out that while 'eczema is not fully preventable, its onset and flare-ups can be significantly reduced' through stress management, early treatment, avoiding triggers, and maintaining a healthy skin barrier with the use of breathable clothing and moisturisers to protect the skin barrier. Other highlights of the MoU, the signing of which was witnessed by EDS vice president Dr. Muna Al Murrawi and EDS-Scientific Committee head Dr. Fatima Albreiki: n The delivery of educational tools which include colouring books to help understand their condition while storybooks foster empathy and hope. n The delivery of lifestyle magazines and quick guides for families, caregivers and other support individuals to complete lifestyle modification among the patients. n The delivery of resources and other materials for healthcare professionals.
Yahoo
25-06-2025
- Business
- Yahoo
Stifel Downgrades Zoetis (ZTS) Stock, Reduces PT
Zoetis Inc. (NYSE:ZTS) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Stifel analyst Jonathan Block downgraded Zoetis Inc. (NYSE:ZTS)'s stock to 'Hold' from 'Buy,' reducing the price objective to $160 from $165. The firm warned that revenue growth might fall short of Wall Street expectations over the upcoming 2 years as competition intensifies throughout key product categories. While there are longer-term opportunities in oncology and kidney disease, the firm believes that these markets will develop more slowly. A veterinarian administering a vaccine to a herd of cattle in a farm. As per the firm, while Zoetis Inc. (NYSE:ZTS) dealt effectively with competition in the past, this time the competition might prove to be more successful. Stifel's survey identified that there is robust veterinarian interest in Merck's pending Atopic Dermatitis JAK inhibitor and Elanco's CQ – chloroquine. However, Zoetis Inc. (NYSE:ZTS) continues to advance innovation and care for animals throughout the globe. Simparica Trio gained a new label indication in the US to prevent Dipylidium caninum (flea tapeworm) infections by killing Ctenocephalides felis vector fleas in treated dogs. Now, Simparica Trio happens to be the only canine combination parasiticide indicated to prevent flea tapeworm infections, at the source, by killing vector fleas before the transmission. Polen Capital, an investment management company, released its Q4 2024 investor letter. Here is what the fund said: 'Zoetis Inc. (NYSE:ZTS) and Adobe were also notable absolute detractors. Zoetis has been posting excellent growth on the back of its pain and dermatology franchises for quite some time, and its core companion animal business has been firing on all cylinders. Despite this, the stock has come under pressure due to concerns about the growth prospects of Librela, its biologic drug for pain in dogs (as well as Solensia, the sister drug for cats). There has been some concern about the side effects of these drugs, but the data disclosed thus far shows a very low level of adverse events, with drugs that prove highly effective in treating pain. We expect strong growth from these and other drugs currently marketed by Zoetis, with more to come from its prolific pipeline. We used the recent weakness to add to our position.' While we acknowledge the potential of ZTS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZTS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
Business Insider
18-06-2025
- Business
- Business Insider
Zoetis downgraded to Hold from Buy at Stifel
Stifel analyst Jonathan Block downgraded Zoetis (ZTS) to Hold from Buy with a price target of $160, down from $165. The firm contends that the Street's 2026/27 operational revenue growth estimates for Zoetis may 'prove aggressive' as it expects the company's revenue growth rate to decelerate further and compress the stock's multiple or at least prevent a further multiple expansion, the analyst tells investors in a research note. Zoetis has dealt effectively with competition in the past, but this time, competitive inroads may prove more successful, with Stifel's survey identifying strong veterinarian interest in Merck's (MRK) pending Atopic Dermatitis JAK inhibitor and Elanco's (ELAN) CQ – chloroquine – gaining traction, the firm added. Confident Investing Starts Here:
India Today
13-06-2025
- Health
- India Today
Bathing dos and don'ts for babies with sensitive skin
A baby's skin is remarkably delicate, approximately 30% thinner than that of adults, making it more susceptible to moisture loss and irritation. In the summer and monsoon months, factors like heat, humidity and perspiration can further aggravate a baby's delicate skin, but for babies with sensitive skin conditions, these seasonal changes can result in increased rashes and flare-ups. Their skincare regimen needs special care and start by understanding sensitive conditions and why they need extra babies have delicate and sensitive skin, but some are born with or are prone to specific skin conditions such as Atopic Dermatitis (AD), Eczema, Xerosis, and Diaper Dermatitis. We are increasingly seeing a rise in sensitive skin conditions among Indian babies, with the prevalence of AD affecting them at twice the rate of adults globally. Factors like urbanisation, pollution, and climate change, particularly rising temperatures and humidity, have contributed to the growing incidence of conditions like AD. A recent expert consensus from the Indian Academy of Paediatrics (IAP) reports that the prevalence of Atopic Dermatitis in Indian children has increased, ranging between 20% and 39%. Therefore, parents need to adopt science-backed skincare practices to effectively manage these Every day, we meet parents who have many concerns about how to manage these sensitive skin conditions in their babies, especially during bath time. How often should one bathe the baby? Will bathing worsen flare-ups? What cleansers to use? Should one look out for specific ingredients?Here's a comprehensive guide on the dos and don'ts of bathing babies with sensitive skin, emphasizing their comfort, health, and skin integrity. This information is provided by Dr. Karthick Annamalai, MD in Pediatrics, DAA, PGPN, PDFNIC, FAGE, a Consultant Pediatrician, Neonatologist, and specialist in Pediatric Allergy and Asthma at Coimbatore Children's Healthcare in Coimbatore.1. DON'T OVERWASH – KEEP BATH TIME ROUTINE SHORTOverbathing can strip the child's skin of its natural oils, weakening the protective barrier and increasing the risk of dryness, itching, and eczema flare-ups. The Indian Academy of Paediatrics (IAP) recommends that for babies' sensitive skin, the duration of the bath should not exceed 5–10 minutes.[2]They should be bathed in lukewarm water, while avoiding hot baths, as it could further irritate the skin soaps are alkaline and can upset the skin's mildly acidic pH, resulting in further weakening of the stratum corneum. It is recommended to use a soap-free, pH-balanced, fragrance-free, hypoallergenic cleanser. Such products usually have emollient-rich ingredients like glycerine, a humectant that attracts moisture into the skin, providing hydration while carefully stripping sweat, sebum, and environmental pollutants. Lack of harsh surfactants minimises the chances of dryness or irritation post-wash, which is crucial in peak heat It is recommended to use a soap-free, pH-balanced cleanser, preferably oat-based, that's gentle enough for daily use. Avoid harsh soaps or foaming agents that can disrupt the skin's microbiome.2. POST BATH, ALWAYS APPLY MOISTURISERS TO LOCK IN MOISTUREDuring bathing, the cleanser can remove the skin's natural lipids. Applying a soothing moisturiser immediately after the bath, while the skin is still slightly damp, helps seal in moisture and reinforces the skin barrier. The IAP guidelines support the use of emollients containing ceramides, lipids, n-palmitoyl ethanolamine, and natural colloidal Skip moisturising even if the skin appears fine. Preventive hydration is key to moisturising and is also important to reduce flare-ups in babies with sensitive skin conditions or those at high risk for the same.3. DO CHOOSE INGREDIENTS RICH IN COLLOIDAL OATMEALSeasonal changes with extreme summer and monsoon-related humidity bring challenges like heat, sweat, and increased sensitivity. For babies with sensitive skin, soothing ingredients such as colloidal oats can provide relief, and these natural agents help soften babies' skin and soothe inflammation, reduce itchiness and irritation, and protect the skin against environmental stressors. Further, Oat Extract works with other ingredients to moisturise the baby's Look for products that are hypoallergenic, fragrance-free, and free from harsh chemicals like parabens, sulphates, and Use adult skincare products on babies. Their formulations are not tailored for infant skin and could do more harm than a baby with sensitive skin requires a balanced approach, gentle cleansing, thorough moisturising, and consistent protection. By keeping baths short, using appropriate cleansers and emollients, and ensuring post-bath hydration, parents can help their babies maintain healthy, comfortable skin even during the harsh weather months. Mindful choices in skincare routines can significantly reduce the impact of sensitive skin conditions, promoting a happier and healthier life.
Yahoo
22-05-2025
- Health
- Yahoo
Atopic Dermatitis 68-Market Drug Forecast and Market Analysis to 2033
Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis: 68-Market Drug Forecast and Market Analysis" report has been added to publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for atopic dermatitis, covered in the analyst's report "Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis", published in March 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare and POLI Price Intelligence databases. For more information on the methodology and assumptions used in the analyst's forecast extrapolations, please refer to the Methodology and Assumptions tabs in the Excel model for this analyst estimated that the atopic dermatitis market was $12.0 billion across the 68MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $28.6 billion, increasing at a compound annual growth rate (CAGR) of 9.1%. This strong growth will be fuelled by driven by the launch of 17 late-stage pipeline agents in the 7MM, increase in treatment options for all age groups and severities, high diagnosed prevalence of atopic dermatitis and high treatment rates across all markets in the 7MM, and novel mechanisms of action anticipated to enter the atopic dermatitis market over the forecast Overview of AD - including epidemiology, disease etiology and management.? Topline AD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs in the 7MM.? Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.? Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.? Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers and barriers. Reasons to Buy Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.? Develop business strategies by understanding the trends shaping and driving the atopic dermatitis (AD) therapeutics market.? Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AD market in the future.? Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.? Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.? Track drug sales in the seven-market AD therapeutics market from 2023-2033.? Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.? Key Topics Covered: 1 Executive Summary1.1 Overview1.2 68M summary statistics1.3 Key 7MM events driving the 68M forecast extrapolation2 Appendix2.1 Abbreviations2.2 Methodology2.2.1 Patient-based forecast methodology2.2.2 68M forecast extrapolation methodology2.3 Primary research - key opinion leaders interviewed for this report2.4 Primary research - prescriber survey2.5 About the authors2.5.1 Analyst2.5.2 Managing analyst2.5.3 Therapy area directors2.5.4 Epidemiologist2.5.5 Epidemiology reviewers2.5.6 Vice President of Disease Intelligence and Epidemiology2.5.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence3 About the AnalystCompanies Featured AbbVie Aclaris Therapeutics Acrotech Biopharma Amgen AOBiome Therapeutics Arcutis Biotherapeutics Astria Therapeutics Dermavant Eli Lilly Galderma GlaxoSmithKline Incyte Japan Tobacco Kyowa Kirin LEO Pharma Maruho Nektar Otsuka Pfizer Regeneron Sanofi Torii Pharmaceutical Union Therapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
